Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
InBody Co.,Ltd (041830.KQ)
KRW52,400.00
+800.00 (+1.55%)
KR KOE Healthcare Medical - Specialties
Address
InBody Building 6106
Seoul, KR
Seoul, KR
CEO
Ki-Chul Cha
Website
inbody.com/global
IPO
2000-12-15
ISIN KR7041830001
Description
InBody Co.,Ltd is a global provider of advanced body composition analysis solutions. The company offers an extensive product line, including body composition analyzers, blood pressure monitors, stadiometers, and body water analyzers, along with specialized devices like the InBody Dial and various bands. These technologies are widely employed across diverse applications, such as medical specialties like nephrology, liver disease, and diabetes, as well as in nutrition and rehabilitation programs. Originally established in 1996 and headquartered in Seoul, South Korea, the company was formerly known as Biospace Co., Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW52,400.00
+800.00 (+1.55%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
93.9K
Beta
0.59
Float Shares
8.17M
Free Float %
61.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.03% | -4.68% | +55.42% | +43.28% | +47.19% | +40.43% | +86.76% | +69.50% | +53.60% | +0.11% | +1,966.24% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
52,400.00
DCF (Unlevered)
154,845.92
+195.5%
DCF (Levered)
151,572.31
+189.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
10.47
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
8 / 10
Strong MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
4 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%+14.4% ★ Q1'26: +23.1% (vs Q1'25)
-
EPS growth Medical - Specialties: +10.1%-4.8% Q1'26: +121.4% (vs Q1'25)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+8.8% Q1'26: +13.1% (vs Q1'25)
-
EBIT margin Medical - Specialties: +12.6%+15.4% ★ Q1'26: +19.0% (vs Q1'25)
-
ROIC Medical - Specialties: +6.6%+14.6% ★ Q1'26: +24.7% (vs Q1'25)
-
Share dilution Medical - Specialties: 0.0%+1.8% Q1'26: +6.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×0.23× ★ Q1'26: 0.14× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
68.95B
est: 69.38B (-0.6%)
|
79.85B
est: 79.66B (+0.2%)
|
93.25B
est: 91.70B (+1.7%)
|
99.64B
est: 99.90B (-0.3%)
|
117.06B
est: 116.45B (+0.5%)
|
107.12B
est: 107.10B (+0.0%)
|
137.84B
est: 138.00B (-0.1%)
|
160.00B
est: 160.00B (+0.0%)
|
170.35B
est: 171.50B (-0.7%)
|
204.46B
est: 200.50B (+2.0%)
|
233.95B
est: 232.20B (+0.8%)
|
276.55B
276.55B – 276.55B
+19.1% YoY
|
322.90B
322.90B – 322.90B
+16.8% YoY
|
378.05B
378.05B – 378.05B
+17.1% YoY
|
| EBITDA |
21.38B
est: 19.30B (+10.7%)
|
23.79B
est: 22.16B (+7.3%)
|
26.65B
est: 25.51B (+4.5%)
|
25.69B
est: 27.80B (-7.6%)
|
32.30B
est: 32.40B (-0.3%)
|
25.30B
est: 29.80B (-15.1%)
|
43.77B
est: 38.40B (+14.0%)
|
47.99B
est: 44.52B (+7.8%)
|
48.84B
est: 47.72B (+2.3%)
|
51.31B
est: 53.98B (-5.0%)
|
44.71B
est: 62.52B (-28.5%)
|
74.46B
74.46B – 74.46B
+19.1% YoY
|
86.94B
86.94B – 86.94B
+16.8% YoY
|
101.78B
101.78B – 101.78B
+17.1% YoY
|
| EBIT |
20.01B
est: 16.84B (+18.8%)
|
22.04B
est: 19.34B (+14.0%)
|
24.90B
est: 22.26B (+11.9%)
|
24.71B
est: 24.25B (+1.9%)
|
28.32B
est: 28.27B (+0.2%)
|
20.79B
est: 26.00B (-20.0%)
|
39.33B
est: 33.50B (+17.4%)
|
42.75B
est: 38.84B (+10.1%)
|
42.88B
est: 41.63B (+3.0%)
|
44.23B
est: 47.08B (-6.0%)
|
36.09B
est: 54.52B (-33.8%)
|
64.93B
64.93B – 64.93B
+19.1% YoY
|
75.82B
75.82B – 75.82B
+16.8% YoY
|
88.77B
88.77B – 88.77B
+17.1% YoY
|
| Net Income |
17.31B
est: 17.04B (+1.6%)
|
16.99B
est: 16.18B (+5.0%)
|
19.32B
est: 18.25B (+5.9%)
|
19.67B
est: 20.06B (-2.0%)
|
20.43B
est: 19.94B (+2.5%)
|
17.52B
est: 16.52B (+6.0%)
|
34.03B
est: 32.37B (+5.1%)
|
33.82B
est: 32.48B (+4.1%)
|
36.72B
est: 34.70B (+5.8%)
|
33.14B
est: 32.23B (+2.8%)
|
30.63B
est: 32.31B (-5.2%)
|
41.96B
41.96B – 41.96B
+29.9% YoY
|
48.22B
48.22B – 48.22B
+14.9% YoY
|
58.81B
58.81B – 58.81B
+22.0% YoY
|
| SGA |
10.29B
est: 15.50B (-33.6%)
|
11.61B
est: 17.80B (-34.8%)
|
14.44B
est: 20.49B (-29.5%)
|
16.94B
est: 22.32B (-24.1%)
|
19.75B
est: 26.02B (-24.1%)
|
17.54B
est: 23.93B (-26.7%)
|
52.43B
est: 30.83B (+70.1%)
|
25.75B
est: 35.74B (-28.0%)
|
32.65B
est: 38.31B (-14.8%)
|
45.06B
est: 47.63B (-5.4%)
|
54.86B
est: 55.16B (-0.6%)
|
65.70B
65.70B – 65.70B
+19.1% YoY
|
76.71B
76.71B – 76.71B
+16.8% YoY
|
89.81B
89.81B – 89.81B
+17.1% YoY
|
| EPS |
1,271.68
est: 1,314.85 (-3.3%)
|
1,247.88
est: 1,248.43 (0.0%)
|
1,430.26
est: 1,408.26 (+1.6%)
|
1,458.98
est: 1,548.13 (-5.8%)
|
1,531.73
est: 1,538.50 (-0.4%)
|
1,335.40
est: 1,275.00 (+4.7%)
|
2,612.57
est: 2,498.00 (+4.6%)
|
2,595.83
est: 2,506.00 (+3.6%)
|
2,819.01
est: 2,677.50 (+5.3%)
|
2,546.18
est: 2,442.00 (+4.3%)
|
2,423.00
est: 2,448.00 (-1.0%)
|
3,179.50
3,179.50 – 3,179.50
+29.9% YoY
|
3,653.50
3,653.50 – 3,653.50
+14.9% YoY
|
4,456.00
4,456.00 – 4,456.00
+22.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-28 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-27 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-26 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-22 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-15 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
48.82B
OE per share TTM
3,749.66
Owner's Yield
7.92%
Maintenance CapEx ratio
35.24%
Maint CapEx / Avg PPE
50.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
135.69M
Shares Outstanding
13.34M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ju-Sik Shin | Executive Officer | — | — |
| Ki-Chul Cha | Chief Executive Officer | — | — |
| Yoon-Sun Shin | Managing Director | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 041830.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
